Moneycontrol PRO

business

Glenmark-Sanofi: Too soon to talk valuations, says Espirito

Chirag Talati, analyst at Espirito Santo Securities Pharma, in an interview with CNBC-TV18's Sonia Shenoy and Anuj Singhal, gave his perspective on the Glenmark-Sanofi deal and why he is bearish on Dr Reddy's and Ranbaxy.

first published: May 17, 2011 03:02 pm

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347